New nusinersen drug delivery method identified for spinal muscular atrophy patients
STRASBURG, PA- A new report has identified an alternative method to deliver nusinersen to patients with spinal muscular atrophy (SMA)
Read more
Early treatment with nusinersen can mean better outcomes for babies
Spinal muscular atrophy (SMA) is a genetic disease that affects motor neurons in the spinal cord, resulting in muscle atrophy
Read more